Cover Image
市場調查報告書

門脈高壓症:開發中產品分析

Portal Hypertension - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213081
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
門脈高壓症:開發中產品分析 Portal Hypertension - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 69 Pages
簡介

門脈高壓症是被稱為門脈的靜脈系統血壓上昇。血壓上升造成肝臟內血流阻塞。症狀有腹水、血小板和白血球含量低、消化道出血、腦病變、混亂和健忘症等。門脈高壓症的最常見的原因是肝硬化。

本報告提供門脈高壓症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

門脈高壓症概要

治療藥的開發

  • 開發中產品:概要

開發中的治療藥:各企業

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Conatus Pharmaceuticals Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Galectin Therapeutics, Inc.
  • Genextra S.p.a.
  • LinXis B.V.
  • Mezzion Pharma Co. Ltd.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發暫停中的計劃

開發中止的計劃

產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8425IDB

Summary

Global Markets Direct's, 'Portal Hypertension - Pipeline Review, H2 2016', provides an overview of the Portal Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Portal Hypertension
  • The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Portal Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Portal Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Portal Hypertension Overview
  • Therapeutics Development
  • Pipeline Products for Portal Hypertension - Overview
  • Portal Hypertension - Therapeutics under Development by Companies
  • Portal Hypertension - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Portal Hypertension - Products under Development by Companies
  • Portal Hypertension - Companies Involved in Therapeutics Development
    • Conatus Pharmaceuticals Inc.
    • Cumberland Pharmaceuticals, Inc.
    • Galectin Therapeutics, Inc.
    • Genextra S.p.a.
    • LinXis B.V.
    • Mezzion Pharma Co. Ltd.
  • Portal Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • emricasan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ifetroban sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LIN-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Portal Hypertension - Dormant Projects
  • Portal Hypertension - Discontinued Products
  • Portal Hypertension - Product Development Milestones
    • Featured News & Press Releases
      • Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
      • ep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis
      • Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
      • Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
      • Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension
      • Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Portal Hypertension, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
  • Portal Hypertension - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016
  • Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Portal Hypertension - Pipeline by Genextra S.p.a., H2 2016
  • Portal Hypertension - Pipeline by LinXis B.V., H2 2016
  • Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Portal Hypertension - Dormant Projects, H2 2016
  • Portal Hypertension - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Portal Hypertension, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top